Melanie Bhatnagar, Sarah Sheehan, Isha Sharma, Gerri Baer, Dionna Green, Susan McCune, Steven Joffe, and Donna Snyder
Pediatrics, 2021Read More
Characterizing the FDA’s Approach to Benefit-Risk Assessment throughout the Medical Product Life Cycle
Nicholas R. Harrison and Sarah Sheehan
Christina Silcox, Isha Sharma, & Arti Rai.
FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes
Matthew Rosenberg, Sarah Sheehan, Esther Zhou, Ellen Pinnow, Jessica Burnell, Morgan Romine, Gerald Dal Pan